Recipharm attains major sustainability milestones
· Approval of ambitious Greenhouse Gas emission reduction targets by SBTi · Commitment to renewable electricity sourcing to 100.0% by 2024 and to 42.1% GHG emission reduction (Scope 1 and 2) by 2030 · Elevated CDP Climate rating to B levelRecipharm, a global leader in contract development and manufacturing, has announced two major milestones as part of its ongoing commitment to sustainability, underpinning the Group’s pledge to minimising its environmental impact. Firstly, the Science Based Targets initiative (SBTi) has approved Recipharm’s near-term science-based emissions